DURATOCIN Trademark

Trademark Overview

On Monday, April 4, 2022, a trademark application was filed for DURATOCIN with the United States Patent and Trademark Office. The USPTO has given the DURATOCIN trademark a serial number of 97345459. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Monday, June 17, 2024. This trademark is owned by Ferring B.V.. The DURATOCIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products and preparations for use in the treatment of reproductive and maternal health conditions, diseases and disorders
duratocin

General Information

Serial Number97345459
Word MarkDURATOCIN
Filing DateMonday, April 4, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateMonday, June 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 30, 2023

Trademark Statements

Goods and ServicesPharmaceutical products and preparations for use in the treatment of reproductive and maternal health conditions, diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 8, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameFerring B.V.
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressHoofddorp 2132 JX
NL
Party NameFerring B.V.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressHoofddorp 2132 JX
NL

Trademark Events

Event DateEvent Description
Tuesday, June 28, 2022NON-FINAL ACTION E-MAILED
Thursday, April 7, 2022NEW APPLICATION ENTERED
Friday, April 8, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, June 26, 2022ASSIGNED TO EXAMINER
Tuesday, June 28, 2022NON-FINAL ACTION WRITTEN
Tuesday, June 28, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 21, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 21, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 22, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 24, 2023NON-FINAL ACTION WRITTEN
Tuesday, January 24, 2023NON-FINAL ACTION E-MAILED
Tuesday, January 24, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 17, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, April 17, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 17, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 25, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 10, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 30, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 30, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 25, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, November 29, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 29, 2023SOU EXTENSION 1 FILED
Wednesday, November 29, 2023SOU EXTENSION 1 GRANTED
Thursday, November 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 17, 2024SOU TEAS EXTENSION RECEIVED
Monday, June 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 17, 2024SOU EXTENSION 2 GRANTED
Monday, June 17, 2024SOU EXTENSION 2 FILED
Monday, July 1, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, July 1, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, July 1, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, July 1, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, July 1, 2024TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

Related Keywords

duratocin health conditions diseases disorders maternal reproductive products preparations treatment pharmaceutical